GSK Wins Early FDA Approval for Nelkarmi Lung Cancer Drug
The FDA approved Nelkarmi ahead of its original decision deadline, based on Phase I/II ALKOVE-1 trial data showing clinically meaningful, durable responses in patients previously treated with ALK inhibitors.
The approval came ahead of the FDA's original decision deadline and was based on data from the ALKOVE-1 Phase I/II trial, which demonstrated clinically meaningful and durable responses in patients who had previously received ALK inhibitor therapies. GSK said the next-generation treatment was specif…